Glenmede Trust’s Mersana Therapeutics MRSN Stock Holding History

Glenmede Trust’s Portfolio MRSN Stock Details MRSN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-1	Closed	–	–	1841
2020 Q3	$0	Buy	+1	New	+$505	﹤0.01%	2542

Other funds holding MRSN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Glenmede Trust's MRSN Position: Q4 2020 in Review

Glenmede Trust sold out of Mersana Therapeutics (MRSN) in Q4 2020, closing a stake of 1 share.

Glenmede Trust first reported a position in MRSN in Q3 2020 and held it in 1 quarter. The position peaked at $0 in Q3 2020. 151 funds tracked by Wall St. Rank hold MRSN as of Q4 2020.

Glenmede Trust reported no remaining Mersana Therapeutics position as of Q4 2020 after selling out during the quarter.
Glenmede Trust sold 1 Mersana Therapeutics share in Q4 2020.
Glenmede Trust first reported a position in Mersana Therapeutics in Q3 2020 and held it in 1 quarter.
Glenmede Trust's Mersana Therapeutics position peaked at $0 in Q3 2020.
151 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q4 2020.

Based on Glenmede Trust's 13F filing for Q4 2020, filed 16 Feb 2021.